Navigation Links
Neurocrine Biosciences Reports Fourth Quarter and Year-End 2008 Results
Date:2/3/2009

SAN DIEGO, Feb. 3 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter and year ended December 31, 2008. For the three months ended December 31, 2008, the Company reported a net loss of $28.9 million or $0.75 loss per share compared to a net loss of $128.0 million or $3.35 loss per share for the same period last year. For the year ended December 31, 2008, the Company had a net loss of $88.6 million or $2.30 loss per share compared to a net loss of $207.3 million or $5.45 loss per share in 2007. The decrease in net loss is primarily the result of a one-time write down in 2007 of $94.0 million for asset impairment related to a prepaid royalty, coupled with the fourth quarter of 2007 restructuring and ongoing cost control measures throughout 2008.

Revenues for the fourth quarter of 2008 were $0.7 million compared with $0.5 million for the same period last year. Revenues for the year ended December 31, 2008, were $4.0 million, compared with $1.2 million for 2007. The increase in revenues for the year ended December 31, 2008 is primarily due to revenue recognized under the Dainippon Sumitomo Pharma Co. Ltd. (DSP) collaboration agreement. The Company recognized $2.9 million and $0.5 million in license fee revenue from DSP during 2008 and 2007, respectively.

Research and development expenses were $11.9 million in the fourth quarter of 2008 compared to $24.3 million for the fourth quarter of 2007. For the year ended December 31, 2008, research and development expenses were $55.3 million compared to $82.0 million last year. The decrease in quarterly and year-to-date research and development expenses is primarily due to cost savings arising from our restructuring during the fourth quarter of 2007, and ongoing cost control measures throughout 2008.


'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Webcast Alert: Neurocrine Announces 1Q08 Financial Results
2. Neurocrine Announces Closing of $109 Million Sale and Leaseback Agreement for its Real Estate Assets
3. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
4. Enlight Biosciences Expands to direct up to $52 Million to Transformational Enabling Technologies
5. New Jersey-Based Biotech Start-Up Nexomics Biosciences Gets Off the Ground
6. URMC, Lighthouse Biosciences Awarded U.S. Patent for Diagnostic Technology
7. URMC, Lighthouse Biosciences awarded US patent for diagnostic technology
8. Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis
9. CeloNova BioSciences Receives FDA Market Approval for Embozene(TM) Color-Advanced Microspheres Embolization Platform
10. Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus
11. Alexander R. Giaquinto, Ph.D., Joins Regado Biosciences as Senior Vice President of Regulatory Affairs and Quality Assurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... HealthDay Reporter TUESDAY, ... such as Adderall, Ritalin and Concerta -- used to ... growth, a new study suggests. "Stimulant medication did ... researcher Dr. Slavica Katusic, an associate professor of pediatrics ... noted that results of earlier studies have been mixed, ...
(Date:9/2/2014)... (HealthDay News) -- Drinking and marijuana may lead to ... study suggests. Researchers analyzed 2007 to 2011 data ... who said they had used alcohol or marijuana at ... was associated with more unsafe driving, damage to relationships ... while under the influence of alcohol, especially among females. ...
(Date:9/2/2014)... ALEXANDRIA, VAThe latest research on sleep apnea, tonsillectomies, ... otolaryngic topics will be presented in Orlando, FL, ... OTO EXPO℠ of the American Academy of OtolaryngologyHead ... meeting of ear, nose, throat, head and neck ... research to be presented were released today, and ...
(Date:9/2/2014)... Last year, SIGVARIS took graduated compression ... a luxurious line of graduated compression socks with natural fibers. ... Socks are joining the SIGVARIS MEDICAL collection for those who ... of natural cotton fibers. , “When people step into ... socks as soft as the finest cashmere,” says Clay Walker, ...
(Date:9/2/2014)... September 02, 2014 The exclusive ClinicCRM ... was designed to help doctors manage foreign patient flow, ... patient conversion rates and clink revenue. Since its launch ... increase in sales revenue and a 70 percent increase ... in their own healthcare practices. , With its ease ...
Breaking Medicine News(10 mins):Health News:ADHD Medications Won't Stunt Kids' Growth, Study Finds 2Health News:ADHD Medications Won't Stunt Kids' Growth, Study Finds 3Health News:Booze, Pot Bad for Teens in Different Ways, Study Suggests 2Health News:SIGVARIS’ Luxury Line of Compression Socks, SEA ISLAND COTTON, Now Available in Stronger Compression Level 2Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 2Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 3Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 4
... ... ... ... ...
... ... ... ... ...
... CREST trial that compared traditional surgery with less-invasive stenting ... is being called "seminal and robust." The Carotid ... safety and efficacy of both procedures are roughly equal. ... is one of the largest randomized stroke prevention trials ...
... , ... California Dental Hygienists’ Association Conducts Statewide Outreach Efforts to Provide Low-Income Children Access ... ... National Children’s Dental Health Month draws to a close, California’s dental hygienists ...
... ago, researchers say, , FRIDAY, Feb. 26 (HealthDay News) -- ... than 12,000 years ago, new research suggests. , The researchers ... a major determinant of small size in dogs. The gene ... the Middle Eastern gray wolf, according to the study, published ...
... newcomers hold mettle against warfarin, aspirin , FRIDAY, Feb. ... that the mainstays of anti-clotting therapy, namely warfarin and ... , Researchers presenting their findings during a Friday news ... San Antonio show that one new drug, dabigatran (Pradaxa), ...
Cached Medicine News:Health News:High Representative Ashton and Commissioner Georgieva to Visit Haiti 2Health News:High Representative Ashton and Commissioner Georgieva to Visit Haiti 3Health News:High Representative Ashton and Commissioner Georgieva to Visit Haiti 4Health News:American National Announces Corrected Dividend Dates 2Health News:Stents as good as surgery for clogged carotid arteries 2Health News:California Dental Hygienists Say National Children's Dental Health Month Should Be a Yearlong Effort 2Health News:California Dental Hygienists Say National Children's Dental Health Month Should Be a Yearlong Effort 3Health News:Current Blood Thinners Face Tough Competition 2Health News:Current Blood Thinners Face Tough Competition 3
(Date:9/2/2014)... , España, September 2, 2014 ... de fibrilación atrial muestran agentes antitrombóticos no utilizados ... -- Las presentaciones de GARFIELD-AF en ... el tratamiento y los resultados de pacientes en ... diaria --    Los datos de ...
(Date:9/2/2014)... , September 2, 2014 ... ESC CONGRESS 2014 provide insight into treatment and ... everyday clinical practice --   Data ... Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF), an ... stroke prevention strategies for atrial fibrillation (AF) patients ...
(Date:9/2/2014)... 2, 2014  Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ... of the company at the Morgan Stanley Global Healthcare Conference ... Presentation date: Tuesday September 9, 2014 , Presentation time: ... and 30-day archive of this presentation will be available at ... Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused ...
Breaking Medicine Technology:Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 2Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 3Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 4Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 5Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 6Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 7Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 8Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 9Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 10Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 11Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9
... Langan, Vice President of Marketing and Business Development, announced ... labeling for sterile intravenous compounded ICU Services at ... May 19-24, 2012 in Orlando, Florida. (Logo: ... care professionals to visit Booth #2668 to see how ...
...  Varian Medical Systems (NYSE: VAR ) will ... and other conditions non-invasively at the 2012 International Conference ... in San Francisco.  "We,re excited about ... not be familiar with radiosurgery as a treatment option ...
Cached Medicine Technology:PharMEDium Highlights Enhanced Labeling for ICU Services at Critical Care Expo 2Varian Medical Systems to Showcase Radiosurgery Technology for Non-invasive Treatment of Early Stage Inoperable Lung Cancer 2Varian Medical Systems to Showcase Radiosurgery Technology for Non-invasive Treatment of Early Stage Inoperable Lung Cancer 3Varian Medical Systems to Showcase Radiosurgery Technology for Non-invasive Treatment of Early Stage Inoperable Lung Cancer 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: